Clinical Trial Update: Sodium Nitroprusside in Early Course Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sodium nitroprusside for early-course schizophrenia was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Sodium nitroprusside (sodium nitroprusside)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: TERMINATED | Results posted: 2025-12-10